We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+42.53%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$3.08B
AUM Growth
+$924M
(+43%)
Cap. Flow
+$642M
Cap. Flow
% of AUM
20.83%
Top 10 Holdings %
Top 10 Hldgs %
38.34%
Holding
121
New
53
Increased
26
Reduced
7
Closed
25
Avg Time Held Equity + Options
0.2
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.2
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$122M |
| 2 |
Eli Lilly
LLY
|
+$121M |
| 3 |
Maravai LifeSciences
MRVI
|
+$96M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$78.7M |
| 5 |
Avantor
AVTR
|
+$51.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$104M |
| 2 |
Merck
MRK
|
+$94.9M |
| 3 |
Biogen
BIIB
|
+$81.3M |
| 4 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$67.1M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$52.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.11% |
| 2 | Miscellaneous | 3.78% |
| 3 | Technology | 1.87% |
| 4 | Financials | 0.18% |
| 5 | Industrials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Avantor
AVTR
$10.9B
| $185M | 6% |
6,566,700
+2,004,300
| +44% | +$51.7M |
2020 Q2
2 quarters
|
|
2
Arvinas
ARVN
$468M
| $152M | 4.93% |
1,787,358
+439,058
| +33% | +$15.1M |
2020 Q2
2 quarters
|
|
3
AbbVie
ABBV
$501B
| $145M | 4.72% |
1,356,000
-166,800
| -11% | -$16M |
2019 Q4
4 quarters
|
|
|
4
Eli Lilly
LLY
$1.12T
| $137M | 4.44% |
+810,500
| New | +$121M |
2020 Q4
0 quarters
|
|
|
5
AstraZeneca
AZN
$259B
| $115M | 3.73% |
+1,150,000
| New | +$122M |
2020 Q4
0 quarters
|
|
|
6
Maravai LifeSciences
MRVI
$1.05B
| $96.7M | 3.14% |
+3,445,772
| New | +$96M |
2020 Q4
0 quarters
|
|
7
Quest Diagnostics
DGX
$26.4B
| $94.4M | 3.06% |
792,100
+390,100
| +97% | +$47.6M |
2020 Q3
1 quarter
|
|
|
8
BioMarin Pharmaceuticals
BMRN
$10.8B
| $87.1M | 2.83% |
+992,900
| New | +$78.7M |
2020 Q4
0 quarters
|
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $85.5M | 2.78% |
1,169,300
+239,100
| +26% | +$17.8M |
2019 Q4
4 quarters
|
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $83.5M | 2.71% |
380,000
+105,000
| +38% | +$22.7M |
2020 Q3
1 quarter
|
|
11
NovaBridge Biosciences American Depositary Shares
NBP
$149M
| $75M | 2.44% |
1,591,000
+251,000
| +19% | +$9.88M |
2020 Q3
1 quarter
|
|
12
Syndax Pharmaceuticals
SNDX
$1.22B
| $73.6M | 2.39% |
3,308,000
+1,453,900
| +78% | +$30.2M |
2020 Q2
2 quarters
|
|
|
13
CALL
Biogen
BIIB
$34.8B
| $60.7M | 1.97% |
248,100
+34,000
| +16% | +$8.77M |
2020 Q3
1 quarter
|
|
14
Zentalis Pharmaceuticals
ZNTL
$212M
| $59M | 1.91% |
1,135,000
+230,881
| +26% | +$10.4M |
2020 Q2
2 quarters
|
|
|
CHNG
15
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $57.5M | 1.87% |
3,082,100
+554,600
| +22% | +$9.11M |
2020 Q3
1 quarter
|
|
16
Shattuck Labs
STTK
$555M
| $49.2M | 1.6% |
+938,813
| New | +$30.2M |
2020 Q4
0 quarters
|
|
17
Natera
NTRA
$58.3B
| $47.8M | 1.55% |
479,800
-23,600
| -5% | -$1.97M |
2020 Q3
1 quarter
|
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $47.7M | 1.55% |
+621,000
| New | +$46.5M |
2020 Q4
0 quarters
|
|
19
DELISTED
ChemoCentryx, Inc.
CCXI
| $46.9M | 1.52% |
+757,000
| New | +$43.3M |
2020 Q4
0 quarters
|
|
|
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
| $46.9M | 1.52% |
3,185,200
+1,439,200
| +82% | +$20.8M |
2020 Q3
1 quarter
|
|
|
21
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $44.7M | 1.45% |
+521,100
| New | +$44.2M |
2020 Q4
0 quarters
|
|
22
DELISTED
Apellis Pharmaceuticals
APLS
| $44.3M | 1.44% |
774,000
+150,700
| +24% | +$6.37M |
2020 Q3
1 quarter
|
|
23
Cardinal Health
CAH
$58.7B
| $43.3M | 1.41% |
+808,000
| New | +$41.9M |
2020 Q4
0 quarters
|
|
|
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $42.2M | 1.37% |
491,800
-792,400
| -62% | -$67.1M |
2020 Q1
3 quarters
|
|
25
Organogenesis Holdings
ORGO
$143M
| $41.6M | 1.35% |
+5,521,500
| New | +$26.2M |
2020 Q4
0 quarters
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q4 2020 Portfolio in Review
As of Q4 2020, Avidity Partners Management held 121 positions worth $3.08B, up 43% from $2.16B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Avidity Partners Management deployed $642M of net new capital in Q4 2020, opening 53 new positions and adding to 26 existing holdings. Its largest new stake was AstraZeneca: 1,150,000 shares worth $115M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $67.1M trimmed.
- Avidity Partners Management's largest Q4 2020 buy was AstraZeneca: 1,150,000 shares worth $115M.
- Avidity Partners Management added most to Avantor in Q4 2020, an estimated $51.7M increase.
- Avidity Partners Management's biggest Q4 2020 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $67.1M.
- Avidity Partners Management fully exited Seagen Inc. Common Stock in Q4 2020, selling an estimated $104M.
- Avidity Partners Management's ten largest holdings make up 38% of its $3.08B portfolio in Q4 2020.
- Avidity Partners Management opened 53 new positions and closed 25 in Q4 2020.
- Avidity Partners Management's portfolio value rose 43% quarter-over-quarter to $3.08B.
Based on Avidity Partners Management's 13F filing for Q4 2020, filed 16 Feb 2021.